Kuwait’s Gulf Care to invest $260M in Uzbekistan’s pharma sector

Uzbekistan has engaged in negotiations with three major Kuwaiti pharmaceutical companies, according to Abdulla Azizov, Director of the Agency for the Development of the Pharmaceutical Industry, in an interview with “Uzbekistan 24” TV channel.

Among them, Al Imtiaz Investment Group intends to establish contract-based pharmaceutical production in Uzbekistan, setting up its own manufacturing facilities.

Gulf Care General Trading Co, whose representatives have already visited Tashkent, has agreed to mutually beneficial contracts worth $260 million, covering four key areas:

-  Diagnostic centers – Establishing state-of-the-art medical diagnostic centers across multiple regions.

-  Pharmaceutical manufacturing – Setting up production facilities in five regions of Uzbekistan.

-  Education and workforce development – Training medical professionals and facilitating employment abroad.

-  Advanced laboratories – Enhancing diagnostic services through the creation of modern laboratories.

Additionally, Kuwait Saudi Pharmaceutical Industries Company has expressed interest in collaborating with Uzbekistan, with company representatives scheduled to visit the country within the next 2–3 months.

Dr. Eyad Al Saleh, Chairman of Gulf Care General Trading Co, confirmed that an initial investment of $260 million will be directed toward major healthcare projects in Tashkent, Fergana, Bukhara, Syrdarya, and other regions.

Beyond the pharmaceutical sector, Uzbekistan and Kuwait have also signed agreements to collaborate in various industries during President Shavkat Mirziyoyev’s official visit to Kuwait. The agreements cover industrial development, labor market cooperation, smart cities, infrastructure projects, agriculture, hydropower, healthcare, logistics, and transportation.